Catalent Inc (CTLT) Shares Bought by Northern Trust Corp

Catalent Inc (CTLT) Shares Bought by Northern Trust Corp

Northern Trust Corp increased its position in shares of Catalent Inc (NASDAQ:CTLT) by 6.2% during the third quarter, Holdings Channel reports. The institutional investor owned 1,685,175 shares of the company’s stock after buying an additional 98,044 shares during the period. Northern Trust Corp owned approximately 1.35% of Catalent worth $43,545,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the stock. FMR LLC boosted its stake in Catalent by 89.1% in the second quarter. FMR LLC now owns 14,597,087 shares of the company’s stock worth $335,587,000 after buying an additional 6,877,549 shares in the last quarter. Vanguard Group Inc. boosted its stake in Catalent by 15.2% in the second quarter. Vanguard Group Inc. now owns 7,881,737 shares of the company’s stock worth $181,201,000 after buying an additional 1,039,117 shares in the last quarter. BlackRock Fund Advisors boosted its stake in Catalent by 15.0% in the third quarter. BlackRock Fund Advisors now owns 6,579,877 shares of the company’s stock worth $170,024,000 after buying an additional 858,781 shares in the last quarter. Janus Capital Management LLC boosted its stake in Catalent by 1.5% in the second quarter. Janus Capital Management LLC now owns 5,061,371 shares of the company’s stock worth $116,361,000 after buying an additional 73,233 shares in the last quarter. Finally, State Street Corp boosted its stake in Catalent by 19.1% in the second quarter. State Street Corp now owns 3,603,669 shares of the company’s stock worth $82,846,000 after buying an additional 576,973 shares in the last quarter.

Catalent Inc (NASDAQ:CTLT) traded down 2.25% on Friday, hitting $26.89. The stock had a trading volume of 1,019,243 shares. Catalent Inc has a one year low of $18.92 and a one year high of $32.24. The stock has a market cap of $3.35 billion and a price-to-earnings ratio of 32.20. The stock’s 50 day moving average is $26.53 and its 200 day moving average is $25.14.

Catalent (NASDAQ:CTLT) last released its quarterly earnings data on Monday, November 7th. The company reported $0.16 EPS for the quarter, topping analysts’ consensus estimates of $0.15 by $0.01. The firm earned $442.20 million during the quarter, compared to analysts’ expectations of $430.26 million. The business’s revenue for the quarter was up 4.5% compared to the same quarter last year. During the same quarter last year, the business earned $0.18 earnings per share. Analysts anticipate that Catalent Inc will post $1.38 earnings per share for the current year.

A number of equities research analysts recently issued reports on CTLT shares. Stephens started coverage on shares of Catalent in a research note on Tuesday, October 18th. They issued an “overweight” rating and a $31.00 price target on the stock. Goldman Sachs Group, Inc. (The) started coverage on shares of Catalent in a research note on Thursday, December 1st. They set a “neutral” rating and a $25.00 target price on the stock. Zacks Investment Research raised shares of Catalent from a “strong sell” rating to a “hold” rating and set a $26.00 target price on the stock in a research note on Monday, October 31st. Jefferies Group LLC reaffirmed a “hold” rating and set a $28.00 target price on shares of Catalent in a research note on Tuesday, November 8th. Finally, KeyCorp started coverage on shares of Catalent in a research note on Wednesday, October 19th. They set an “overweight” rating and a $29.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the stock. Catalent presently has a consensus rating of “Hold” and a consensus target price of $28.14.

Catalent Company Profile

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.

Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent Inc (NASDAQ:CTLT).

Related posts

Leave a Comment